The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a positive outlook on Teladoc Health's fundamentals but acknowledges short-term challenges or valuation adjustments. This could lead to mixed reactions in the market, potentially stabilizing the stock price as investors digest the implications of the lowered price target against the backdrop of an Outperform rating.